Zydus Lifesciences shares climbed to an intraday excessive of Rs 993.80 on Thursday. The inventory is up about 8% over the previous month and 10% over the previous yr. Over the long term, Zydus Lifesciences has delivered a 93% return in three years and almost 61% over 5 years.
Zydus Lifesciences share buyback
In an change submitting launched on Wednesday, Zydus Lifesciences introduced that its board of administrators will meet on Might 19 to think about and approve its outcomes for the January-March quarter of the monetary yr 2026. Together with the earnings, the board may also contemplate a proposal to purchase again absolutely paid-up fairness shares of the corporate, it additional mentioned.
This comes after Zydus Lifesciences’ Rs 600 crore share buyback at a worth of Rs 1,005 apiece by way of the tender route. The buyback worth implied a premium of almost 9% from the extent at which the inventory was buying and selling on the report date. Earlier than that, the corporate executed a Rs 750-crore share buyback in 2022.
Zydus Lifesciences publicizes acquisition of Assertio Holdings
Zydus Lifesciences on Wednesday introduced that it has entered into an settlement to amass US-based pharma firm Assertio Holdings for $166.40 million. Assertio is targeted on speciality and oncology supportive-care therapies.
“Zydus Worldwide DMCC, a subsidiary of the corporate, has signed a definitive settlement, by way of its wholly owned acquisition subsidiary Zara Merger Sub Inc, with Assertio Holdings to amass all excellent shares of Assertio for $23.50 per share in money,” in response to the assertion.
Additionally learn: NLC India shares rally 18% to contemporary report excessive after This autumn web revenue skyrockets 189% YoYThis comes after The Financial Instances reported that Zydus Lifesciences is near buying a US-based drugmaker. Sources within the funding banking circles advised ET that Zydus will get a lift for the reason that goal firm has its personal pipeline of biologic medication. For a number of months, Zydus Lifesciences has been methods to develop its pipeline of modern medication. It was additionally seen in discussions with Ardelyx just a few months in the past, however the talks didn’t materialise. “Zydus has been in discussions with at the very least three firms,” the supply talked about.
(Disclaimer: Suggestions, recommendations, views and opinions given by the consultants are their very own. These don’t characterize the views of The Financial Instances)
